First interactions with EMA – Q&A 7
What regulatory pathway missteps should we avoid, and how can we streamline our EU dossier preparation?
What’s Inside the Q&A:
Pathway Selection Pitfalls
Why choosing the wrong regulatory route especially for biotech products can delay approval and waste time.
Dossier Preparation Best Practices
Key EMA-specific requirements (like RMPs, multilingual labeling, and PIPs) that must be addressed early to avoid validation failures.
Clock Stop Management
How to plan ahead for EMA’s milestone-based reviews, ensuring your team is ready to respond quickly and completely.
Strategic Use of EU Designations
When and how to leverage Orphan, PRIME, and accelerated assessment pathways – distinct from U.S. fast-track programs.
